Phaseline

Targets › CLL1

CLL1 (C-type lectin domain family 12 member A): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Myeloid inhibitory C-type lectin receptor that acts as a negative regulator of myeloid cell activation. Myeloid cell inhibition is required to limit pro-inflammatory pathways and protect against excessive inflammation (By similarity). (UniProt, Q5QGZ9)

Open in Phaseline: the race on CLL1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicineanti-CLL-1 CAR NK cells
anti-CLL-1 chimeric antigen receptor NK cells
CLL1Phase 1Relapsed Adult AMLMar 2027

Conditions

Relapsed Adult AML (1)

Modalities

other (1)

Companies

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.